PURPOSE: Hormone resistance remains a significant clinical problem in prostate cancer with few therapeutic options. Research into mechanisms of hormone resistance is essential. EXPERIMENTAL DESIGN: We analyzed 38 paired (prehormone/posthormone resistance) prostate cancer samples using the Vysis GenoSensor. Archival microdissected tumor DNA was extracted, amplified, labeled, and hybridized to Amplionc I DNA microarrays containing 57 oncogenes. RESULTS: Genetic instability increased during progression from hormone-sensitive to hormone-resistant cancer (P = 0.008). Amplification frequencies of 15 genes (TERC, MYBL3, HRAS, PI3KCA, JUNB, LAMC2, RAF1, MYC, GARP, SAS, FGFR1, PGY1, MYCL1, MYB, FGR) increased by >10% during hormone escape. Receptor tyrosine kinases were amplified in 73% of cases; this was unrelated to development of hormone resistance. However, downstream receptor tyrosine kinase signaling pathways showed increased amplification rates in resistant tumors for the mitogen-activated protein kinase (FGR/Src-2, HRAS, and RAF1; P = 0.005) and phosphatidylinositol 3'-kinase pathways (FGR/Src-2, PI3K, and Akt; P = 0.046). Transcription factors regulated by these pathways were also more frequently amplified after escape (MYC family: 21% before versus 63% after, P = 0.027; MYB family: 26% before versus 53% after, P = 0.18). CONCLUSIONS: Development of clinical hormone escape is linked to phosphatidylinositol 3'-kinase and mitogen-activated protein kinase pathways. These pathways may function independently of the androgen receptor or via androgen receptor activation by phosphorylation, providing novel therapeutic targets.
PURPOSE: Hormone resistance remains a significant clinical problem in prostate cancer with few therapeutic options. Research into mechanisms of hormone resistance is essential. EXPERIMENTAL DESIGN: We analyzed 38 paired (prehormone/posthormone resistance) prostate cancer samples using the Vysis GenoSensor. Archival microdissected tumor DNA was extracted, amplified, labeled, and hybridized to Amplionc I DNA microarrays containing 57 oncogenes. RESULTS: Genetic instability increased during progression from hormone-sensitive to hormone-resistant cancer (P = 0.008). Amplification frequencies of 15 genes (TERC, MYBL3, HRAS, PI3KCA, JUNB, LAMC2, RAF1, MYC, GARP, SAS, FGFR1, PGY1, MYCL1, MYB, FGR) increased by >10% during hormone escape. Receptor tyrosine kinases were amplified in 73% of cases; this was unrelated to development of hormone resistance. However, downstream receptor tyrosine kinase signaling pathways showed increased amplification rates in resistant tumors for the mitogen-activated protein kinase (FGR/Src-2, HRAS, and RAF1; P = 0.005) and phosphatidylinositol 3'-kinase pathways (FGR/Src-2, PI3K, and Akt; P = 0.046). Transcription factors regulated by these pathways were also more frequently amplified after escape (MYC family: 21% before versus 63% after, P = 0.027; MYB family: 26% before versus 53% after, P = 0.18). CONCLUSIONS: Development of clinical hormone escape is linked to phosphatidylinositol 3'-kinase and mitogen-activated protein kinase pathways. These pathways may function independently of the androgen receptor or via androgen receptor activation by phosphorylation, providing novel therapeutic targets.
Authors: Bekir Cinar; Filiz Kisaayak Collak; Delia Lopez; Seckin Akgul; Nishit K Mukhopadhyay; Murat Kilicarslan; Daniel G Gioeli; Michael R Freeman Journal: Cancer Res Date: 2011-04-21 Impact factor: 12.701
Authors: Bin Zhong; David A Sallman; Danielle L Gilvary; Daniele Pernazza; Eva Sahakian; Dillon Fritz; Jin Q Cheng; Ioannis Trougakos; Sheng Wei; Julie Y Djeu Journal: Mol Cancer Ther Date: 2010-05-25 Impact factor: 6.261
Authors: Shazia Irshad; Mukesh Bansal; Mireia Castillo-Martin; Tian Zheng; Alvaro Aytes; Sven Wenske; Clémentine Le Magnen; Paolo Guarnieri; Pavel Sumazin; Mitchell C Benson; Michael M Shen; Andrea Califano; Cory Abate-Shen Journal: Sci Transl Med Date: 2013-09-11 Impact factor: 17.956
Authors: Paul C Boutros; Michael Fraser; Nicholas J Harding; Richard de Borja; Dominique Trudel; Emilie Lalonde; Alice Meng; Pablo H Hennings-Yeomans; Andrew McPherson; Veronica Y Sabelnykova; Amin Zia; Natalie S Fox; Julie Livingstone; Yu-Jia Shiah; Jianxin Wang; Timothy A Beck; Cherry L Have; Taryne Chong; Michelle Sam; Jeremy Johns; Lee Timms; Nicholas Buchner; Ada Wong; John D Watson; Trent T Simmons; Christine P'ng; Gaetano Zafarana; Francis Nguyen; Xuemei Luo; Kenneth C Chu; Stephenie D Prokopec; Jenna Sykes; Alan Dal Pra; Alejandro Berlin; Andrew Brown; Michelle A Chan-Seng-Yue; Fouad Yousif; Robert E Denroche; Lauren C Chong; Gregory M Chen; Esther Jung; Clement Fung; Maud H W Starmans; Hanbo Chen; Shaylan K Govind; James Hawley; Alister D'Costa; Melania Pintilie; Daryl Waggott; Faraz Hach; Philippe Lambin; Lakshmi B Muthuswamy; Colin Cooper; Rosalind Eeles; David Neal; Bernard Tetu; Cenk Sahinalp; Lincoln D Stein; Neil Fleshner; Sohrab P Shah; Colin C Collins; Thomas J Hudson; John D McPherson; Theodorus van der Kwast; Robert G Bristow Journal: Nat Genet Date: 2015-05-25 Impact factor: 38.330
Authors: Urszula L McClurg; Nay C T H Chit; Mahsa Azizyan; Joanne Edwards; Arash Nabbi; Karl T Riabowol; Sirintra Nakjang; Stuart R McCracken; Craig N Robson Journal: Oncogene Date: 2018-05-14 Impact factor: 9.867